(Q38270419)

1 September 2017

1 reference

title

HMG-CoA reductase inhibitors as adjuvant treatment for hematologic malignancies: what is the current evidence? (English)

1 reference

1 September 2017

Bruno Bockorny

1

1 reference

1 September 2017

Constantin A Dasanu

series ordinal

2

1 reference

1 September 2017

publication date

23 November 2014

1 reference

1 September 2017

1 reference

1 September 2017

volume

94

1 reference

1 September 2017

issue

1

1 reference

1 September 2017

page(s)

1-12

1 reference

The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators

1 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS00277-014-2236-4

The statins in preventive cardiology.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-014-2236-4

Statins, stem cells, and cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-014-2236-4

Measurement of C-reactive protein for the targeting of statin therapy in the primary prevention of acute coronary events

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-014-2236-4

Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-014-2236-4

Pharmacokinetic and pharmacodynamic alterations of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors: drug-drug interactions and interindividual differences in transporter and metabolic enzyme functions

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-014-2236-4

Pharmacological actions of statins: a critical appraisal in the management of cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-014-2236-4

Pharmacokinetics of high-dose simvastatin in refractory and relapsed chronic lymphocytic leukemia patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-014-2236-4

Follow-up study of patients randomized in the Scandinavian simvastatin survival study (4S) of cholesterol lowering

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-014-2236-4

Cholesterol lowering with statin drugs, risk of stroke, and total mortality. An overview of randomized trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-014-2236-4

Do statins cause cancer? A meta-analysis of large randomized clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-014-2236-4

Safety and tolerability of pravastatin in long-term clinical trials: prospective Pravastatin Pooling (PPP) Project

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-014-2236-4

Relationship between lipid levels and clinical outcomes in the Long-term Intervention with Pravastatin in Ischemic Disease (LIPID) Trial: to what extent is the reduction in coronary events with pravastatin explained by on-study lipid levels?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-014-2236-4

Assessing possible hazards of reducing serum cholesterol

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-014-2236-4

The association between 3-hydroxy-3-methylglutaryl conenzyme A inhibitor use and breast carcinoma risk among postmenopausal women: a case-control study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-014-2236-4

Mortality and incidence of cancer during 10-year follow-up of the Scandinavian Simvastatin Survival Study (4S).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-014-2236-4

Statins and the risk of colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-014-2236-4

Statins and prostate cancer risk: a case-control study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-014-2236-4

The role of statins in cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-014-2236-4

Statin use and risk of lymphoid neoplasms: results from the European Case-Control Study EPILYMPH.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-014-2236-4

Prescription medications associated with a decreased risk of non-Hodgkin's lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-014-2236-4

Prior medical conditions and medication use and risk of non-Hodgkin lymphoma in Connecticut United States women

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-014-2236-4

Cancer risk among statin users: a population-based cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-014-2236-4

Use of statins and risk of haematological malignancies: a meta-analysis of six randomized clinical trials and eight observational studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-014-2236-4

Regulation of the mevalonate pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-014-2236-4

Myopathy induced by HMG-CoA reductase inhibitors in rabbits: a pathological, electrophysiological, and biochemical study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-014-2236-4

Targeting oncogenic Ras signaling in hematologic malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-014-2236-4

The widening role of statins: RAS signal transduction and drug-induced cytotoxicity in human leukemia: a commentary to 'interaction of cytosine arabinoside and lovastatin in human leukemia cells'.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-014-2236-4

Suppressive effects of statins on acute promyelocytic leukemia cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-014-2236-4

On the factors modulating the effect of statins on malignant cell proliferation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-014-2236-4

A cell cycle-regulated inhibitor of cyclin-dependent kinases

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-014-2236-4

Inhibition of the 3-hydroxy-3-methylglutaryl-coenzyme A reductase pathway induces p53-independent transcriptional regulation of p21(WAF1/CIP1) in human prostate carcinoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-014-2236-4

Lovastatin mediated G1 arrest in normal and tumor breast cells is through inhibition of CDK2 activity and redistribution of p21 and p27, independent of p53.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-014-2236-4

HMG-CoA reductase inhibitor mevastatin enhances the growth inhibitory effect of butyrate in the colorectal carcinoma cell line Caco-2

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-014-2236-4

Lovastatin-induced RhoA modulation and its effect on senescence in prostate cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-014-2236-4

Inhibition of isoprenoid biosynthesis induces apoptosis in human promyelocytic HL-60 cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-014-2236-4

Effect of simvastatin alone and in combination with cytosine arabinoside on the proliferation of myeloid leukemia cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-014-2236-4

Evaluation of apoptosis and necrosis induced by statins using fluorescence-enhanced flow cytometry

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-014-2236-4

Statins are active in acute lymphoblastic leukaemia (ALL): a therapy that may treat ALL and prevent avascular necrosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-014-2236-4

Simvastatin induces apoptosis of B-CLL cells by activation of mitochondrial caspase 9.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-014-2236-4

Mechanism of simvastatin-induced K562 cell apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-014-2236-4

Statins activate the mitochondrial pathway of apoptosis in human lymphoblasts and myeloma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-014-2236-4

Role for protein geranylgeranylation in adult T-cell leukemia cell survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-014-2236-4

Blocking protein geranylgeranylation is essential for lovastatin-induced apoptosis of human acute myeloid leukemia cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-014-2236-4

Inhibition of protein geranylgeranylation induces apoptosis in myeloma plasma cells by reducing Mcl-1 protein levels

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-014-2236-4

Blocking the Raf/MEK/ERK pathway sensitizes acute myelogenous leukemia cells to lovastatin-induced apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-014-2236-4

Cholesterol-modulating agents kill acute myeloid leukemia cells and sensitize them to therapeutics by blocking adaptive cholesterol responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-014-2236-4

Lovastatin induces a pronounced differentiation response in acute myeloid leukemias

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-014-2236-4

HMG-CoA reductase inhibitors and the malignant cell: the statin family of drugs as triggers of tumor-specific apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-014-2236-4

Mechanisms of angiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-014-2236-4

The evolving role of statins in the management of atherosclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-014-2236-4

Effects of statins on vascular wall: vasomotor function, inflammation, and plaque stability

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-014-2236-4

Simvastatin treatment is associated with improvement in coronary endothelial function and decreased cytokine activation in patients after heart transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-014-2236-4

Statins have biphasic effects on angiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-014-2236-4

Co-operation between endothelin and nitric oxide in promoting endothelial cell migration and angiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-014-2236-4

The HMG-CoA reductase inhibitor simvastatin activates the protein kinase Akt and promotes angiogenesis in normocholesterolemic animals

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-014-2236-4

Lovastatin Inhibits VEGFR and AKT Activation: Synergistic Cytotoxicity in Combination with VEGFR Inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-014-2236-4

Arsenic trioxide induces apoptosis of Burkitt lymphoma cell lines through multiple apoptotic pathways and triggers antiangiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-014-2236-4

Bevacizumab potentiates chemotherapeutic effect on T-leukemia/lymphoma cells by direct action on tumor endothelial cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-014-2236-4

Correlation between high vascular endothelial growth factor-A serum levels and treatment outcome in patients with standard-risk acute lymphoblastic leukemia: a report from Children's Oncology Group Study CCG-1962.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-014-2236-4

Targeting vascular endothelial growth factor for relapsed and refractory adult acute myelogenous leukemias: therapy with sequential 1-beta-d-arabinofuranosylcytosine, mitoxantrone, and bevacizumab

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-014-2236-4

Interaction of cytosine arabinoside and lovastatin in human leukemia cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-014-2236-4

The HMG-CoA inhibitor, simvastatin, triggers in vitro anti-tumour effect and decreases IgM secretion in Waldenstrom macroglobulinaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-014-2236-4

Simvastatin and purine analogs have a synergic effect on apoptosis of chronic lymphocytic leukemia cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-014-2236-4

Lovastatin potentiates antitumor activity of doxorubicin in murine melanoma via an apoptosis-dependent mechanism

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-014-2236-4

Activation of nuclear factor-kappa B pathway by simvastatin and RhoA silencing increases doxorubicin cytotoxicity in human colon cancer HT29 cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-014-2236-4

Lovastatin induces apoptosis of ovarian cancer cells and synergizes with doxorubicin: potential therapeutic relevance

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-014-2236-4

Reversal of chemoresistance and enhancement of apoptosis by statins through down-regulation of the NF-kappaB pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-014-2236-4

Inhibition of the mevalonate pathway potentiates the effects of lenalidomide in myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-014-2236-4

Lovastatin and thalidomide have a combined effect on the rate of multiple myeloma cell apoptosis in short term cell cultures.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-014-2236-4

Statins impair antitumor effects of rituximab by inducing conformational changes of CD20

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-014-2236-4

Concomitant statin use does not impair the clinical outcome of patients with diffuse large B cell lymphoma treated with rituximab-CHOP.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-014-2236-4

Statin use and prognosis in patients with diffuse large B-cell lymphoma and follicular lymphoma in the rituximab era

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-014-2236-4

Imatinib for newly diagnosed patients with chronic myeloid leukemia: incidence of sustained responses in an intention-to-treat analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-014-2236-4

Imatinib 800 mg daily induces deeper molecular responses than imatinib 400 mg daily: results of SWOG S0325, an intergroup randomized PHASE II trial in newly diagnosed chronic phase chronic myeloid leukaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-014-2236-4

Clinical and biologic activity of the farnesyltransferase inhibitor R115777 in adults with refractory and relapsed acute leukemias: a phase 1 clinical-laboratory correlative trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-014-2236-4

Farnesyltransferase inhibitors and their potential role in therapy for myelodysplastic syndromes and acute myeloid leukaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-014-2236-4

A randomized phase 3 study of tipifarnib compared with best supportive care, including hydroxyurea, in the treatment of newly diagnosed acute myeloid leukemia in patients 70 years or older.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-014-2236-4

Suppression of farnesyltransferase activity in acute myeloid leukemia and myelodysplastic syndrome: current understanding and recommended use of tipifarnib

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-014-2236-4

K- and N-Ras are geranylgeranylated in cells treated with farnesyl protein transferase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-014-2236-4

Thalidomide, dexamethasone and lovastatin with autologous stem cell transplantation as a salvage immunomodulatory therapy in patients with relapsed and refractory multiple myeloma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-014-2236-4

A phase II clinical trial does not show that high dose simvastatin has beneficial effect on markers of bone turnover in multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-014-2236-4

High dose simvastatin does not reverse resistance to vincristine, adriamycin, and dexamethasone (VAD) in myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-014-2236-4

Lipid-Lowering Drug Use and Breast Cancer in Older Women: A Prospective Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-014-2236-4

Diagnosis and antimicrobial therapy of lung infiltrates in febrile neutropenic patients (allogeneic SCT excluded): updated guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Medical Oncology (DGHO).

21 January 2018

1 reference

5 May 2024

https://opencitations.net/index/api/v1/citations/10.1093/ANNONC/MDU192

Identifiers

DOI

10.1007/S00277-014-2236-4

1 reference

1 September 2017

1 reference